AN2 Therapeutics, Inc.

An2 Therapeutics Inc. is a clinical-stage biopharmaceutical company focusing on the development and commercialization of innovative therapies for infectious diseases with high unmet medical needs. The company's primary purpose is to address significant gaps in current treatment options, particularly for non-tuberculous mycobacterial (NTM) lung disease, which lacks effective and safe therapies. This sector is critically important as drug-resistant infections continue to pose a global health challenge. An2 Therapeutics leverages cutting-edge research and development strategies to create potential new medicines that could significantly advance the field of infectious disease treatment. The company's efforts in addressing such critical healthcare issues position it as a notable player in the biopharmaceutical industry, aiming to bring novel, life-saving therapeutics to market. Its role in the financial market is underscored by its potential to contribute to public health solutions while offering investors participation in the growth of the healthcare sector.